MDXG, US6024961012

MiMedx stock: Cantor Fitzgerald reiterates Overweight rating

Published on 11/19/2026 at 03:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cantor Fitzgerald kept its Overweight view and an USD 8.00 target on MiMedx stock. The company is shifting its portfolio toward surgical care.

Analyst view stays constructive

  • Cantor Fitzgerald kept its Overweight view on MiMedx.
  • MiMedx develops biologic products for wound care, burns and surgical procedures.
  • The company reported third-quarter revenue of USD 62.28 million on October 28.
MDXG, US6024961012, Illustration mit AI erstellt.

MiMedx stock is in focus after Cantor Fitzgerald reiterated its Overweight rating and an USD 8.00 price target on Tuesday, November 17, 2026. MarketBeat reported that the research note maintained the brokerage's constructive stance on the medical technology company.

Rating remains constructive

The reiterated rating follows MiMedx's third-quarter results, which included revenue of USD 62.28 million and earnings per share of negative USD 0.01, according to the MarketBeat report. Revenue came in below the analyst estimate of USD 68.56 million, keeping execution and demand in wound care important considerations for investors.

MarketBeat said six analysts had Buy ratings on the shares and one had a Sell rating. Its reported consensus was Moderate Buy, with an average price target of USD 8.14. The Cantor Fitzgerald target therefore remains one of the more bullish reference points in the analyst group, although price targets are expectations rather than guarantees.

Surgical portfolio gains importance

MiMedx said at its November investor conference that surgical products accounted for about two-thirds of revenue in the third quarter. Management also described the surgical franchise as the faster-growing part of the business, while reimbursement changes continue to weigh on wound-care activity.

Business and competitive setting

MiMedx develops and markets biologic products made from donated human placental tissue. Its portfolio includes amniotic membrane and umbilical cord allografts for wound care and surgical procedures, including the EpiFix product, and the company uses its PURION processing method for donated tissue. Headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States and also has selected international sales. Its activities span wound care, burns and surgery, positioning it as a specialist regenerative-medicine supplier rather than a broad-based medical-device manufacturer.

MiMedx at a glance

  • Company: MiMedx Group, Inc.
  • ISIN: US6024961012
  • Ticker: MDXG
  • Primary exchange: Nasdaq
  • Headquarters: Marietta, Georgia
  • Focus: Biologic products for wound care, burns and surgical procedures

The broader U.S. market environment is covered in S&P 500 market reports.

More news and analyses on MiMedx stock are available on the company topic page.

Disclaimer...
en | US6024961012 | MDXG | boerse | 70533413 | bgmi